

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person* <u>Morrison Susan</u> (Last) (First) (Middle) 12400 HIGH BLUFF DRIVE (Street) SAN DIEGO CA 92130 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>TANDEM DIABETES CARE INC [TNDM]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>EVP & Chief Admin. Officer</u>
	3. Date of Earliest Transaction (Month/Day/Year) 05/29/2026	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Restricted Stock Unit	(1)	05/29/2026		A		29,136		(2)	(2)	Common Stock	29,136	\$0	29,136	D	

Explanation of Responses:

- Each restricted stock unit (RSU) represents a contingent right to receive either one share of the Issuer's common stock or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).
- One-third of such RSUs shall vest on 5/29/2027, and the remaining RSUs shall vest in eight (8) equal quarterly installments on the 15th of the month thereafter subject to the terms of the 2023 Plan.

Remarks:

Ex. 24: Power of Attorney

/s/ Jerilyn Laskie, Attorney-in-Fact for Susan M. Morrison 06/02/2026

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

SUBSTITUTE POWER OF ATTORNEY

Pursuant to written powers of attorney (each, a “Power of Attorney”) by the individuals listed below, the undersigned, Shannon M. Hansen, has been constituted and appointed the true and lawful attorney-in-fact of such individuals, with full power of substitution, to execute and file documents with the U.S. Securities and Exchange Commission pursuant to Section 16(a) of the Securities Exchange Act of 1934, as amended, with respect to equity securities of Tandem Diabetes Care, Inc. and with such further powers as specified in each Power of Attorney.

<u>Individual</u>	<u>Date of Power of Attorney</u>
Dick P. Allen	April 19, 2022
Sandra W. Beaver	November 11, 2025
Ricky A. Carpenter	April 21, 2022
Myoungil Cha	June 15, 2022
Elizabeth A. Gasser	April 19, 2022
Peyton R. Howell	April 20, 2022
Jean-Claude Kyrillos	June 21, 2024
Joao Malagueira	June 15, 2022
Kathleen McGroddy-Goetz	April 21, 2022
Susan M. Morrison	April 21, 2022
Rebecca B. Robertson	April 20, 2022
John F. Sheridan	April 20, 2022
Rajwant S. Sodhi	April 21, 2022
Christopher J. Twomey	April 20, 2022
Leigh A. Vosseller	April 20, 2022

In accordance with the authority granted under each Power of Attorney, including the power of substitution, the undersigned hereby appoints Jerilyn Laskie as a substitute attorney-in-fact, on behalf of the individuals listed above, with the full power of substitution, to exercise and execute all of the powers granted or conferred to the undersigned in each Power of Attorney.

For the avoidance of doubt, the foregoing appointment shall not serve as a revocation of the powers granted to the undersigned herself in each Power of Attorney.

This Substitute Power of Attorney shall remain in full force and effect unless and until revoked by the undersigned.

IN WITNESS WHEREOF, the undersigned has caused this Substitute Power of Attorney to be executed as of May 20, 2026.

/s/ Shannon M. Hansen
Shannon M. Hansen, Attorney-in-Fact

